Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.

Verena Wally* (First author), Alain Hovnanian, Juliette Ly, Hana Buckova, Victoria Brunner, Thomas Lettner (Co-author), Michael Ablinger (Co-author), Thomas Felder (Co-author), Peter Hofbauer, Martin Wolkersdorfer, Florian Lagler (Co-author), Wolfgang Hitzl (Co-author), Martin Laimer (Co-author), Sophie Kitzmüller (Co-author), Anja Diem (Co-author), Johann Bauer (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

48 Citations (Web of Science)
Original languageEnglish
Pages (from-to)892-901.e7
JournalJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume78
Issue number5
DOIs
Publication statusPublished - 2018

Keywords

  • EPIDERMAL STEM-CELLS
  • DOWLING-MEARA
  • GENE
  • MUTATIONS
  • AMPLIFICATION
  • DISORDERS
  • KERATIN-5
  • SAFETY
  • EBS

Cite this